Select Page
Responsive Centered YouTube Video
Discussion on the potential impact of engineered bacteria in clinical settings
  • Dr. Philip McMillan and Dr. Shankara Shetty discussing the impact of engineered bacteria. 0:05

  • Dr. Shetty’s focus on COVID-19 from an autoimmune perspective. 0:20

  • Dr. Shetty’s interventions in South Africa to save patients’ lives. 0:29

  • Concerns about the weaponization of bacteria and its potential impact. 0:45

  • Dr. Shetty’s determination to save patients despite threats to his medical license. 1:49

  • Dr. Shetty’s proactive approach in understanding and treating severe illness. 2:05

  • Dr. Shetty’s analysis of clinical data and virus characteristics to develop treatment strategies. 2:23

Insights on early treatment strategies for COVID-19 based on clinical observations and pathophysiological understanding
  • Clinical presentation led to understanding of immunological dysregulation in COVID-19. 2:58

  • Recognized biphasic nature of illness and immune response involvement. 3:12

  • Formulated treatment hypotheses based on known and unknown information. 3:32

  • Published academic paper on observational and clinical findings in May-June 2020. 4:00

  • Advocated for early treatment and pathophysiological research for effective COVID-19 management. 4:24

  • Received recognition for accurate observations and treatment successes. 5:11

Findings of early treatment negating the need for mRNA intervention in the pandemic
  • Discovery of a lab-made pathogen probability leading to critical findings on early treatment. 5:35

  • Lack of acknowledgment shaping decisions and perspective on the pandemic narrative. 7:03

  • Controversial statement on early treatment potentially reducing mortality and morbidity. 7:40

  • Suggestion that mRNA intervention rush to market could have been unnecessary with early treatment solution. 8:03

  • Importance of safety and efficacy in developing a strategy post early treatment confirmation. 8:10

  • The end goal of negating mortality and morbidity to allow time for appropriate strategy development. 8:15

  • Significance of the final point in the May 2020 article on potential solutions without additional interventions. 8:21

Discussion on controversial scientific article, immunity against pathogens, and hope for understanding morbidity
  • Controversial scientific article led to hot water due to vaccine statement. 8:37

  • Consulted peers who praised the scientific article but advised against vaccine mention. 9:22

  • Discussion on serious clinical implications may not be welcomed by all. 10:03

  • Viewers encouraged to follow the link for the full discussion due to sensitivity of some content. 10:11

  • Dr. Shetty observed clinical patterns from the start, providing valuable insights. 10:41

  • Hope given for understanding how pathogens cause morbidity and mortality in hosts. 10:59

  • Immunity is remarkable in combating viruses and bacteria. 11:09

Understanding host responses to pathogens is crucial for combating infections and improving future treatments
  • Immunity is developed through exposure in childhood, allowing us to ignore certain pathogens. 11:16

  • Mortality and morbidity from infections are caused by host responses, not just the virulence of the pathogen. 11:29

  • Virulence of a pathogen is its ability to trigger a serious host response, leading to host mortality. 11:38

  • Understanding and curbing unusual host responses can help in dealing with any pathogen effectively. 11:55

  • Knowledge about how different pathogens trigger cytokine storms is crucial for effective treatments. 12:13

  • Continuing research in this area offers hope for better management of infections in the future. 12:21

  • Stay informed and engaged in the research journey to contribute towards advancements in combating infections. 12:28